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Introduction
Cell mechanisms that lead to apoptosis share some pathways
with cell proliferation. This feature is even more surprising in
differentiated cells such as neurons, in which it was suggested
that a reactivation of the cell cycle is a key step towards
apoptosis (Copani et al., 2001). In fact, neurons of the adult
brain are in G0 phase: they do not divide and are differentiated.
Post-mitotic neuronal cells coming out of G0 phase into G1 are
usually stopped at the G1/S checkpoint and then undergo into
either redifferentiation or apoptosis (Nagy, 2000; Liu and
Greene, 2001a). Therefore, the deregulation of cell-cycle
proteins may be considered to be pathological. It should be
realized that re-expression of G1/S-phase markers is best
correlated to the appearance of apoptosis in neurons. It is
characterized by the formation of the cyclinD1-Cdk4/6
complex, phosphorylation of Rb, dissociation of the Rb-E2F
complex and activation of genes leading to apoptosis (Freeman
et al., 1994; Herrup and Busser, 1995; Osuga et al., 2000; Liu
and Greene, 2001a).
Among the neuronal death inducers, Cdk5 is of particular
interest. Cdk5 is a pro-directed phosphorylation kinase that
belongs to the cyclin-dependent-protein-kinase family.
However, its usual activators do not share any cyclin consensus
sequence and are referred to as p35 and p39. Interestingly, p35
is usually anchored to the membrane because it has a
myristoylation site in its N-terminus. The p35-Cdk5 complex
is abundant in the adult brain and Cdk5 activity increases in
neurons during development. p35 can be proteolysed by
calpains following changes in calcium homeostasis into a
cytosolic C-terminal fragment referred to as p25 that is more
stable than p35 and binds more tightly to Cdk5, leading to a
hyperactive, mislocalized p25-Cdk5 complex (for review, see
Dahavan and Tsai, 2001). Such cleavage of p35 to p25 has been
reported in disorders such as Alzheimer’s disease (AD) and
amyotrophic lateral sclerosis (for reviews, see Patzke and Tsai,
2002; Shelton and Johnson, 2004). Furthermore, exposure of
primary cortical neurons to various insults like Aβ peptide,
H2O2 or glutamate also leads to p25 formation and cell death
(Patrick et al., 1999; Lee et al., 2000; Kusakawa et al., 2000).
However, no mechanisms have been determined by which this
kinase complex triggers its neurotoxicity. It is worth noting
that, in neurodegenerative disorders and cellular models of
neuronal death in which p25-Cdk5 is probably involved,
aberrant cell-cycle deregulation has been reported (Vincent et
al., 1996; Vincent et al., 1997; Vincent et al., 1998; Nagy et
al., 1997; Busser et al., 1998; Copani et al., 1999; Giovanni et
al., 1999; Husseman et al., 2000; Zhu et al., 2000; Ranganathan
et al., 2001; Yang et al., 2003). In addition, a tight correlation
has been established between Cdk5 deregulation and
expression of cell cycle regulatory proteins (Nguyen et al.,
2002; Nguyen et al., 2003). Nevertheless, pathways linking
Cdk5 to cell cycle remain obscure.
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In large models of neuronal cell death, there is a tight
correlation between Cdk5 deregulation and cell-cycle
dysfunction. However, pathways that link Cdk5 to the cell
cycle during neuronal death are still unclear. We have
investigated the molecular events that precede p25/Cdk5-
triggered neuronal death using a neuronal cell line that
allows inducible p25 expression. In this system, no sign of
apoptosis was seen before 24 hours of p25 induction. Thus,
at that time, cell-cycle-regulatory proteins were analysed
by immunoblotting and some of them showed a signiﬁcant
deregulation. Interestingly, after time-course experiments,
the earliest feature correlated with p25 expression was the
phosphorylation of the retinoblastoma protein (Rb).
Indeed, this phosphorylation was observed 6 hours after
p25 induction and was abolished in the presence of a Cdk5
inhibitor, roscovitine, which does not inhibit the usual Rb
cyclin-D kinases Cdk4 and Cdk6. Furthermore, analyses of
levels and subcellular localization of Cdk-related cyclins
did not reveal any change following Cdk5 activation,
arguing for a direct effect of Cdk5 activity on Rb protein.
This latter result was clearly demonstrated by in vitro
kinase assays showing that the p25-Cdk5 complex in our
cell system phosphorylates Rb directly without the need for
any intermediary kinase activity. Hence, Rb might be an
appropriate candidate that connects Cdk5 to cell-cycle
deregulation during neuronal cell death.
Key words: Apoptosis, Cell cycle, E2F-responsive genes, SKNSH-
SY5Y neuroblastoma cells.
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In order to address this question, we used a recently reported
stable neuronal cell line that expresses an inducible p25-Cdk5
activity (Hamdane et al., 2003a). This constitutes a suitable cell
model to follow the sequence of events preceding neuronal
death when there is formation of the p25-Cdk5 complex.
Materials and Methods
Cell culture
p25-inducible SH-SY5Y cells that constitutively express the Tau
isoform with three microtubule-binding domains (2+3–10–) (Tau-
SY5Y) were used as the basis for a tetracycline-regulated mammalian
expression T-Rex system (Invitrogen). Cells were transfected with
inducible expression vector alone (mock cells) or with p25-encoding
cDNA (p25 cells). Individual stable clones were generated and those
that exhibited the weakest basal expression of p25 were selected. For
induction of p25 expression, cells were maintained in medium with
tetracycline at 1 µg ml–1 (Hamdane et al., 2003a).
Cells were grown in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% foetal calf serum, 2 mM L-glutamine, 1 mM
nonessential amino acids, 50 U ml–1 penicillin/streptomycin, 5 µg
ml–1 Blasticidin and 100 µg ml–1 Zeocin (Invitrogen, France) in a
5% CO2 humidiﬁed incubator at 37°C. Cells were differentiated
for 7 days in Dulbecco’s modiﬁed Eagle’s medium or Ham’s F12
medium supplemented with 2 mM L-glutamine, 50 U ml–1
penicillin/streptomycin, 7 µg ml–1 progesterone, 1% insulin-
transferrin-selenium (Invitrogen), 10 ng ml–1 NGF (2.5S subunit,
Sigma). Medium was replenished every 2 days. Roscovitine was
added for 6 hours as described previously (Hamdane et al., 2003a).
Antibodies
Anti-Cdk5 monoclonal antibody (J-3; Santa Cruz Biotechnology,
Tebu-Bio, France), polyclonal antibody against the p35 C-terminus
(C-19; Santa Cruz Biotechnology), antibody against neuron-speciﬁc
γ-enolase (NSE) (Santa Cruz Biotechnology), rabbit polyclonal
antibody against lamin-B (H-90; Santa Cruz Biotechnology), rabbit
polyclonal antibody against p27Kip1 (C-19; Santa Cruz
Biotechnology), rabbit polyclonal antibody against p21Cip1 (C-19,
Santa Cruz Biotechnology), rabbit polyclonal antibody against
caspase-3 (Cell Signaling Technology, Ozyme, France), mouse
monoclonal antibody against Cdc2-p34 (17; Santa Cruz
Biotechnology), rabbit polyclonal antibody against cyclin D that
recognizes cyclin D1 and cross-reacts with cyclin D2 (Cell Signaling
Technology), rabbit polyclonal antibody against cyclin D3 (C-16,
Santa Cruz Biotechnology), rabbit polyclonal antibody against
cyclin A (C-19, Santa Cruz Biotechnology), affinity-puriﬁed rabbit
polyclonal antibody against cyclin B1 (H-20, Santa Cruz
Biotechnology), mouse monoclonal antibody against cyclin E (HE12;
Cell Signaling Technology), rabbit polyclonal antibody against Cdk2
(M2; Santa Cruz Biotechnology), rabbit polyclonal antibody against
Cdk4 (C-22; Santa Cruz Biotechnology), rabbit polyclonal antibody
against Cdk6 (C-21; Santa Cruz Biotechnology), affinity-puriﬁed
rabbit polyclonal IgG against phospho-Rb (Ser807/811) and IgG
against phospho-Rb (Ser795) (Cell Signaling Technology), mouse
monoclonal IgG1 against Rb (IF8; Santa Cruz Biotechnology), rabbit
affinity-puriﬁed antibody against the C terminus of Rb (C-15, Santa
Cruz Biotechnology).
Western blotting
Cells were harvested in ice-cold RIPA modiﬁed buffer [50 mM Tris,
pH 7.4, 1% Nonidet P-40 (NP-40), 1% Triton X-100, 150 mM NaCl,
1 mM EDTA] with protease inhibitors (Complete Mini, Roche
Applied Science) and 125 nM phosphatase inhibitor okadaic acid
(Sigma), sonicated and stirred for 1 hour at 4°C. Cell lysate was
recovered in supernatant after centrifugation at 12,000 g, 4°C for 20
minutes. Protein concentration was determined using the BCA protein
assay kit (Pierce Perbio Science, France). Samples were mixed with
an equal volume of 2× Laemmli sample buffer and dithiothreitol,
and heated for 5 minutes at 100°C; then, 10-20 µg were loaded
onto Nu-PAGE Novex gels (Invitrogen). After transfer, membranes
were blocked in TBS pH 8, 0.05% Tween-20 with 5% skimmed milk
and incubated with primary antibody. Horseradish peroxidase (HRP)
conjugated antibody (Sigma) was used as secondary antibody
and HRP activity was detected with the ECL detection kit
(Amersham Biosciences, France). For immunoblot analyses of
immunoprecipitated complexes and in vitro kinase assays, HRP-
conjugated antibody TrueBlot™ (eBioscience) was used. Restore™
western-blot stripping buffer (Perbio Pierce) was used before
reprobing membranes.
Cytoplasmic and nuclear fractionation
Cells were harvested in ice-cold buffer A (10 mM Hepes, pH 7.9, 1.5
mM MgCl2, 10 mM KCl, 0.15% NP-40) supplemented with protease
inhibitors (Complete Mini) and incubated for 10 minutes on ice. After
centrifugation at 1000 g for 10 minutes, the supernatant was collected
as the cytoplasmic fraction. Nuclei in the pellets were washed three
times and then lysed in ice-cold RIPA modiﬁed buffer with protease
inhibitors (Complete Mini) in an equal volume to that of buffer A.
Centrifugation at 12,000 g at 4°C for 20 minutes allowed the recovery
of the supernatant as the nuclear fraction. The BCA protein assay kit
determined protein concentration.
Immunoprecipitation
Cells (after a 6 hour tetracycline treatment) were harvested in ice-cold
NP-40 lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 0.1% NP-40) supplemented with protease inhibitors, and cell
lysates were prepared as described above. Protein concentration was
determined using the BCA protein assay kit. Cell lysates (800 µg at
4 µg ml–1) were incubated with 1 µg immunoprecipitating antibody
for 1 hour at 4°C and then incubated overnight at 4°C with 20 µl
anti-rabbit-IgG beads (TrueBlot Ig IP Beads, eBioscience).
Immunoprecipitated complexes were washed four times with lysis
buffer (centrifugation at 1000 g at 4°C for 5 minutes), recovered in
40 µl 2× Laemmli buffer with 50 mM of fresh dithiothreitol and boiled
for 5 minutes, and then equal volume of samples were loaded onto
SDS-PAGE gel and analysed by immunoblotting.
In vitro kinase assays
For immunopuriﬁed complexes, immunoprecipitation was performed
as described above. Immunoprecipitated complexes were washed
twice in NP-40 lysis buffer and once in Hepes buffer (40 mM Hepes,
pH 7.2, 8 mM MgCl2) and then used to phosphorylate 2 µg Rb-C
fusion protein (containing Rb residues 701-928 fused to maltose-
binding protein; Cell Signaling Technology) in 30 µl kinase buffer [40
mM Hepes, pH 7, 8 mM MgCl2, 125 nM okadaic acid, protease
inhibitors (EDTA-free Complete Mini, Roche Applied Science), 10
mM ATP]. After incubation for 1 hour at 37°C, the reactions were
stopped by adding 2 Laemmli buffer (1 volume) and boiling for 5
minutes.
For radiolabelled in vitro phosphorylation, kinase assays were
carried out as above by substituting cold ATP with 10 µCi (γ32P)-
ATP. Samples were loaded (equal volumes) onto SDS-PAGE gel.
The gel was then dried and results were visualized using a
phosphorImager
For crude cell lysates, cells were harvested in 10 mM Tris-HCl, pH
7.4, supplemented with protease inhibitors (EDTA-free Complete
Mini) and lysates were prepared as described above. Lysates (200 µg)
were then used to perform in vitro kinase assays under the same
Journal of Cell Science 118 (6)
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experimental procedure as for immunopuriﬁed complexes. When
kinase inhibitors (roscovitine at 10 µM, PD98059 at 50 µM,
SB203580 at 10 µM and SP600125 at 50 µM; Calbiochem) were
used, they were mixed with cell lysates before adding kinase buffer
and Rb-C fusion protein.
Results
Deleterious effect of p25-Cdk5 kinase in differentiated
SY5Y cells
p25-inducible cells were generated from SH-SY5Y cells,
which constitutively overexpress Tau protein (Tau-SY5Y)
(Delobel et al., 2002; Delobel et al., 2003). As previously
shown, p25 protein was not found in mock Tau-SY5Y cells.
Conversely, p25 non-induced cells displayed a low basal
expression of transgene protein, whereas tetracycline treatment
induced high p25 expression, and an active p25-Cdk5 complex
is formed, as shown by coimmunoprecipitation and in-vitro-
phosphorylation experiments (Hamdane et al., 2003a). In this
Tau-SY5Y cell system, Tau overexpression might counteract
toxicity linked to the basal level of p25, because no stable
viable cells were obtained from native SH-SY5Y cells.
Similarly, it has been reported that neuroﬁlament proteins
might serve as a ‘phosphorylation sink’ for p25-Cdk5 complex,
hence sequestering it away from other death-inducing
substrates (Couillard-Després et al., 1998; Nguyen et al., 2001;
Patzke and Tsai, 2002).
In the present cell model, NGF-differentiated cells showed
morphological changes including neurite retraction and the
appearance of rounded cells only after 48 hours of p25
expression (Hamdane et al., 2003a). p25-Cdk5 toxicity was
also investigated at the molecular level in differentiated cells.
Caspase-3 cleavage was analysed at different times of p25
expression (with tetracycline) compared with p25 non-induced
cells (without tetracycline). Caspase-3 activation was observed
after 48 hours of p25 induction, whereas no caspase activity
was detected after 24 hours (Fig. 1). Thus, in order to
investigate the molecular events that precede p25-induced
neuron death, all experiments were ﬁrst performed after 24
hours of p25 induction.
Cell-cycle expression in p25-inducible Tau-SY5Y cells
Several reports show that the reactivation of the cell cycle is
an early marker of neuron death. Thus, we investigated the
expression of cell-cycle proteins in NGF-differentiated
neuronal p25-inducible cells. First, the Cdk inhibitors p21 and
p27 were analysed by western blotting in NGF-differentiated
mock and p25 cells. After 24 hours of p25 induction, no change
in p21 level was observed, whereas a signiﬁcant decrease of
p27 immunoreactivity was seen (Fig. 2A). Similarly, cyclin-A
and -B1 levels were increased. Finally, the immunoreactivity
of the kinase Cdc2-p34 was also increased. None of these
changes was observed in mock cells treated with tetracycline
compared with untreated ones. These results indicated that
there is a deregulation of cell-cycle-regulatory proteins in
p25-induced cells before death. These data are reminiscent of
those observed in neuronal apoptosis and neuroﬁbrillary
degeneration.
Fig. 1. Representative western-blot analysis of caspase-3 cleavage in
a time-course experiment of p25 expression. NGF-differentiated
(7 days) mock and p25 cells were treated (+) or not (–) with
tetracycline for 24 hours or 48 hours, and lysates were analysed
using anti-caspase-3 antibody that recognizes the full-length protein
(35 kDa, arrow) and the large fragments resulting from its cleavage
(19/17 kDa, arrowheads). As positive control, lysates derived from
cells treated (+) or not (–) with 1 µM staurosporine (SSP) were used.
Fig. 2. (A) Representative immunoblot analyses of cell-cycle-regulatory proteins. NGF-differentiated mock and p25 cells were treated (+) or
not (–) with tetracycline for 24 hours and lysates were analysed using antibodies against p21CIP1 (p21), p27KIP1 (p27), cyclin A, cyclin B1 and
p34Cdc2. Equal amounts of proteins were loaded, and visualized with an antibody against neuron-speciﬁc γ-enolase (NSE). (B) Analysis of Rb
phosphorylation in a time-course experiment of p25 expression. Lysates from NGF-differentiated mock and p25 cells treated (+) or not (–) with
tetracycline for 6 hours, 12 hours and 24 hours were ﬁrst immunolabelled with antibodies against Ser807/811-phosphorylated and Ser795-
phosphorylated Rb. After stripping, phosphorylation-independent antibody (IF-8) was used to visualize the amount of loaded Rb (Rb).
Concomitant with this, p25 expression was analysed during the kinetics by antibody against the p35 C-terminus.
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Cell-cycle reactivation was likely mediated through Rb
phosphorylation
Among these cell-cycle genes, some are E2F-responsive genes
encoding proteins including cyclin A and p34-Cdc2. In
this respect, Rb might be of particular interest because its
activity is involved in neuronal cell death and linked to E2F.
In dividing cells, E2F forms an inhibited complex with
hypophosphorylated form of Rb in G0/G1 phase. Inactivation
of Rb by phosphorylation leads to its release from E2F,
allowing transcription of E2F-responsive genes and G1/S-
phase transition. In neuronal cells, Rb protein plays a crucial
role in cell survival because its phosphorylation is tightly
correlated to neuronal death (Galderisi et al., 2003; Greene et
al., 2004).
In the present cell model of p25-Cdk5 neurotoxicity, Rb
phosphorylation status was examined during a time-course
experiment of p25 induction (6 hours, 12 hours and 24 hours
of tetracycline treatment). Rb phosphorylation was visualized
using phosphorylation-dependent antibodies (P-RbSer795
and P-RbSer807/811). Total Rb was then detected using an
antibody recognizing Rb protein independently of its
phosphorylation form (Rb). In controls, no change in Rb-
phosphorylation status was observed between the two
conditions: mock cells treated with tetracycline (+) compared
with untreated ones (–). Conversely, a strong Rb
phosphorylation was present after p25 induction. This
phosphorylation was found as early as 6 hours after p25
induction (Fig. 2B). The different cell cycle markers studied
above (Fig. 2A) were then analysed following 6 hours of
p25 induction. None of them displayed any change in
immunoreactivity at this earlier time of p25 expression (data
not shown).
As shown above, p25 expression was detected as early as 6
hours after tetracycline treatment. We then checked for
formation of p25-Cdk5 complex at this earlier time. As showed
by immunoprecipitation assay (Fig. 3A), Cdk5 is found
associated with p25 protein in 6-hour tetracycline-treated cells.
Furthermore, Rb phosphorylation was analysed in p25-induced
cells in the presence of roscovitine, which speciﬁcally inhibits
Cdk1, Cdk2 and Cdk5 but not cyclin-D-dependent kinases
(Meijer et al., 1997; Meijer et al., 1999). In the present cell
system, Rb phosphorylation was abolished by roscovitine (Fig.
3B), suggesting that it was speciﬁcally triggered by p25-Cdk5
kinase activity.
These data suggest that Rb phosphorylation in our model
was an early event in p25-Cdk5 induced neuronal death.
Nonetheless, it remains to be established whether p25-Cdk5
complex directly phosphorylates Rb or requires activation of
intermediary kinases.
Rb phosphorylation and early cell-cycle-regulatory
proteins
Rb phosphorylation is mainly regulated by cyclin-D-dependent
kinases (Cdk4 and Cdk6). An increase in cyclin-D1 level is
often considered to be necessary to leave G0 phase to G1 in
neurons. Hence, the expression of cyclin D was investigated in
the present cellular model from earlier time of p25 expression
(Fig. 4). No variation in cyclin D1, D2 or D3 levels was
observed following 6 hours of p25 expression (Fig. 4, compare
+ with –). Similarly, western-blot analyses did not show any
increase in the immunoreactivity of cyclins E and A, the Cdk2
regulatory proteins, and the levels of related inhibitory proteins
p21 and p27 did not decrease following p25-induced
expression (Fig. 4). These data suggest that Rb
phosphorylation is probably not associated with an increase in
Journal of Cell Science 118 (6)
Fig. 3. (A) Analysis of p25-Cdk5 complex. Cell lysates from NGF-
p25 and NGF-mock cells (used as negative control), treated for 6
hours with tetracycline, were subjected to immunoprecipitation (IP)
by antibodies against either the p35 C-terminus or Cdk5. Immune
complexes were then analysed by western blotting (WB) with
antibodies against the p35 C-terminus and Cdk5. (B) Analysis of
roscovitine’s effect on earlier Rb phosphorylation. NGF-
differentiated p25 cells were induced (+) or not (–) with tetracycline
for 6 hours in the absence or the presence of 5 µM roscovitine (–/+).
Lysates were immunoblotted with antibody against phospho-
Ser807/811 Rb (P-Rb) followed, after stripping, with the
phosphorylation-independent antibody (IF-8) against Rb protein
(Rb).
Fig. 4. Immunoblot analyses of cell-cycle-regulatory proteins at the
earliest stage of p25 expression. NGF-differentiated p25 cells were
treated (+) or not (–) with tetracycline for 6 hours and lysates were
analysed using the indicated antibodies. Anti-NSE antibody was used
after stripping the membranes to estimate the total amount of loaded
proteins.
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the levels of Cdk4 and Cdk6, and Cdk2-associated cyclins.
However, because Cdk4, Cdk6 and Cdk2 activation could be
linked to a change in cellular redistribution of related cyclins,
western blotting was performed on fractionated cytoplasmic
(Cy) and nuclear (Nu) extracts from mock and p25 cells,
treated with tetracycline for 6 hours. As shown in Fig. 5, proper
fractionation was checked by analysis of cellular distribution
pattern of NSE and lamin B (cytoplasmic and nuclear markers,
respectively).
Results showed that cyclins D1, D2 and D3, as well as their
associated kinases Cdk4 and Cdk6, were mainly detected in the
cytoplasm and their expression patterns were similar between
p25-expressing cells and mock cells. Furthermore, p25
expression did not induce any cellular redistribution of cyclin
A, cyclin E and their associated kinase Cdk2 (Fig. 5). Taken
together, these data strongly suggest that Cdk4, Cdk6 and
Cdk2 activities could not be involved in p25/Cdk5-induced
Rb phosphorylation. Interestingly, analysis of cellular
fractionation showed that p25 and Cdk5 could be detected in
the nuclear fraction of p25-expressing cells (Fig. 5), arguing
for a possible direct Rb phosphorylation by p25-Cdk5
complex.
Rb phosphorylation and the p25-Cdk5 kinase complex
p25 expression did not trigger any change in either the levels
of Cdk4-, Cdk6- and Cdk2-related cyclins or their cellular
localization following 6 hours of tetracycline treatment.
Because, at this time, the only active Cdk was the complex p25-
Cdk5, we asked whether Cdk5 could directly phosphorylate
Rb. To address this question, in vitro kinase assays using Rb-
C fusion protein as substrate were performed by p25-Cdk5
complex from p25-expressing cells.
Monitoring of P-Ser807/811 and P-Ser795 (P-Rb)
immunoreactivities showed that an immunoprecipitated p25-
Cdk5 complex from p25-expressing cells phosphorylates Rb
(Fig. 6A). Conversely, western-blot analyses of in vitro Rb
phosphorylation by immunoprecipitated Cdk2, Cdk4 and Cdk6
revealed no signiﬁcant activity from either mock cells or p25
ones (Fig. 6A). These experiments were conﬁrmed by in vitro
kinase assays in the presence of (γ32P)-ATP (Fig. 6B). These
Fig. 5. Cell fractionation analysis. Cytoplasmic and nuclear fractions
were prepared from NGF-mock and NGF-p25 cells, both treated for
6 hours with tetracycline. For each cell line, 10 µg cytoplasmic
fraction (Cy) and an equivalent volume of the nuclear fraction (Nu)
were analysed by western blotting. Subcellular distribution of the
speciﬁed proteins was visualized using speciﬁc antibodies. The
arrowhead shows cyclin-A immunoreactivity (lower bands), as
determined by comparison with the SDS-PAGE pattern of
immunoprecipitated cyclin A (not shown). Stripped membranes were
reprobed with antibodies against NSE and lamin B to evaluate the
purity of the cytoplasmic and nuclear fractions, respectively.
Fig. 6. Immunoprecipitation and in vitro kinase assays. Lysates from
NGF-mock and NGF-p25 cells, both treated for 6 hours with
tetracycline, were subjected to immunoprecipitation (IP) with the
indicated antibodies. (A) Western-blot analyses. Following in vitro
kinase assays, Rb-C fusion protein (68 kDa) phosphorylation was
evaluated by immunoblotting using P-Rb Ser807/811 and P-Rb
Ser795 antibodies that give similar results (representative
immunoblot with P-Rb Ser807/811 is shown). To evaluate the
amount of loaded Rb-C fusion protein, blots were stripped and
reprobed with a phosphorylation-independent antibody (C-15)
directed against the C terminus of Rb (Rb). The lower sections of
blots were also probed with speciﬁc antibodies to check the presence
of the following proteins: p25, Cdk5, Cdk2, Cdk4 and Cdk6. (B) In
vitro kinase assays in the presence of (γ-32P)ATP. Arrowhead
indicates Rb-C fusion protein with incorporated 32P, which is only
seen in in vitro kinase assay with puriﬁed p25-Cdk5 complex.
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data clearly demonstrate that, in the present cell model, Cdk2,
Cdk4 and Cdk6 were not involved in Rb phosphorylation. It is
worth noting that analyses of immunoprecipitated complexes
showed that p25 protein was associated with Cdk5 and not any
other Cdks (Fig. 6A), conﬁrming that Rb phosphorylation is
exclusively linked to the p25-Cdk5 complex. To conﬁrm this
and to exclude the involvement of other non-studied kinases,
in vitro kinase assays were performed using crude lysate from
6-hour p25-expressing cells in the presence of kinase inhibitors
including roscovitine, PD98059 (MEK1 inhibitor), SB203580
(p38 inhibitor) and SP600125 (JNK inhibitor). Rb
phosphorylation was monitored by western blotting using anti-
phospho-Rb antibodies. As shown in Fig. 7, lysate from p25-
expressing cells (unlike that from mock cells) could
phosphorylate Rb protein. Interestingly, this phosphorylation
was abolished in the presence of the Cdk inhibitor roscovitine,
whereas no effect was shown with the other inhibitors. Hence,
all these data clearly demonstrate that the p25-Cdk5 complex
in the present cell model is involved in a direct phosphorylation
of Rb independent of cyclin-D-associated kinases.
Discussion
A broad range of neuronal cell death models have showed
coexistence between deregulation of Cdk5 activity and
expression of cell-cycle-regulatory proteins (Nguyen et al.,
2002), and a close link between these two events was
established by a recent study (Nguyen et al., 2003).
Furthermore, the p25-Cdk5 complex was shown to be harmful
to neurons, as evidenced by cytoskeleton disruption, neuritic
retraction and expression of apoptotic markers (Ahlijanian et
al., 2000; Bian et al., 2002; Patrick et al., 1999; Hamdane et
al., 2003a). Interestingly, deregulation of Cdk5 activity by
association with its activator p25 is likely to be involved in AD
pathogenesis (Lee et al., 1999; Patrick et al., 1999; Patrick et
al., 2001; Cruz et al., 2003; Noble et al., 2003). Concurrently,
evidence indicates an involvement of cell-cycle-regulatory
elements in neurodegeneration. Indeed, both G1/S- and G2/M-
phase markers are found in neurons undergoing neuroﬁbrillary
degeneration during AD (Vincent et al., 1996; Nagy et al.,
1997; Vincent et al., 1997; Vincent et al., 1998; Busser et al.,
1998; Husseman et al., 2000; Zhu et al., 2000; Dranovsky et
al., 2001; Ranganathan et al., 2001; Hamdane et al., 2003b;
Yang et al., 2003).
We recently showed that the p25-Cdk5 complex induced the
appearance of mitotic epitopes in differentiated neuronal cells
(Hamdane et al., 2003a), which are considered to be early
markers of neuroﬁbrillary degeneration in AD (Vincent et al.,
1998; Augustinack et al., 2002). In this cell system and prior
to neuronal death, p25-Cdk5 kinase induced expression of
regulatory proteins of both G1/S and G2/M phases. The present
data provide an additional support of a tight correlation
between Cdk5 deregulation and expression of cell-cycle
markers during neuronal cell death. Time-course experiments
of p25 expression showed that Rb phosphorylation was an
early event in p25/Cdk5-induced neurotoxicity. This result is
of particular interest because the pathways that mediate the
deleterious effects of p25-Cdk5 kinase in neurons remain
unclear. In neuronal cells, Rb phosphorylation leads to cell
death, probably by subsequent transactivation of E2F-
responsive genes involved in regulation of neuron survival
(Park et al., 2000; Liu and Greene, 2001b; Galderisi et al.,
2003; Greene et al., 2004). Aberrant expression of other E2F-
targeted genes, like some that encode cell-cycle-regulatory
proteins, might also occur. Our results showed an increase in
the levels of E2F-responsive genes, including those encoding
cyclin A and Cdc2-p34, following Rb phosphorylation. This
might explain why both G1/S- and G2/M-phase markers of the
cell cycle are found in degenerating neurons during AD
(Vincent et al., 1997; Husseman et al., 2000).
Some data from the literature suggested that Rb
phosphorylation could be mediated through Cdk5 pathway.
First, Ser residues at positions 807/811 of Rb protein are
located in a consensus sequence with basic residue at position
+3 preferentially targeted by Cdk5 (Songyang et al., 1996;
Sharma et al., 1999). In addition, it has been reported that p25-
Cdk5 complex is able to interact with Rb protein in vitro and
to phosphorylate it (Lee et al., 1997). Because Rb has been
shown to associate with partners such as cyclin D through the
common peptide sequence motif LXCXE, Cdk5 binding might
be mediated by a related sequence motif (LXCXXE) found in
p25 (Lee et al., 1997). Furthermore, p25-Cdk5 is detected in
Journal of Cell Science 118 (6)
Fig. 7. Western blotting of in vitro kinase assays with
crude cell extracts. Lysates from NGF/p25-expressing
cells (6 hours of tetracycline treatment) were used for
Rb-C fusion protein phosphorylation, alone and in the
presence of the kinase inhibitors roscovitine, PD98059,
SB203580 and SP600125. As negative control, an in
vitro kinase assay was performed with lysate from NGF-
mock cells treated for 6 hours with tetracycline.
Phosphorylation of Rb-C fusion protein (P-Rb) was
monitored by P-Rb Ser807/811 and Ser795 antibodies,
which showed similar data. After stripping, membranes
were probed with a phosphorylation-independent
antibody against Rb (C-15) to evaluate the amount of
loaded Rb-C fusion protein (Rb). The lower side of
membrane was analysed by immunoblotting for the
levels of p25 and Cdk5, which attests to the presence of
equivalent amounts of crude lysate in each kinase
reaction.
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the nucleus of degenerating neurons (Patrick et al., 1999) and
interacts with nuclear substrates (Zhang et al., 2002; Gong et
al., 2003). In agreement with that, our experiments showed a
nuclear localization of p25 and Cdk5. Moreover, p25-Cdk5
complex isolated from the present cell system leads to Rb
phosphorylation in vitro.
It is worth noting that an increase in cyclin-D1 level, which
is necessary to exit from G0 phase to G1 in neurons, is often
characterized as an early event leading to Rb phosphorylation
and then neuronal apoptosis. Our data revealed that this
pathway could be a shortcut through the p25-Cdk5 complex
that allows direct Rb phosphorylation. Indeed, in our time-
course experiments, Rb phosphorylation was correlated with
p25 expression. At that time, no variation in the levels or the
subcellular localization of cyclins D1, D2 and D3 was
observed. Besides, Rb phosphorylation was abolished in the
presence of roscovitine. This latter is a Cdc2, Cdk2 and Cdk5
inhibitor but not an inhibitor of cyclin-D-dependent kinases
(Cdk4/Cdk6). More importantly, analysis of Cdk4, Cdk6 and
Cdk2 activities by in vitro kinase assays did not reveal any
change following p25 expression. Finally, in vitro kinase
assays using p25 cell lysate in the presence of kinase inhibitors
clearly demonstrate that Rb protein was directly
phosphorylated by p25-Cdk5 in the current cell system.
Mechanisms by which Cdk5 triggers its deleterious effects
during neurodegeneration are not well elucidated. On one
hand, these effects were related to Tau phosphorylation,
leading to microtubule destabilization (Ahlijanian et al., 2000;
Nguyen et al., 2001; Bu et al., 2002). On the other hand, several
reports, including ours, show a link between Cdk5 and cell-
cycle proteins during neuron death. Activation of cell-cycle
signalling might constitute a crucial step in the neuronal death
pathway inherent to p25-Cdk5 kinase complex. These pieces
of evidence led us to hypothesize that deregulation of Cdk5
triggers the aberrant phosphorylation of different substrates,
involving pathways that will concomitantly promote
neurodegeneration. It will be interesting to perform more
investigations on available models of neuronal death to identify
relevant players for neurodegeneration, allowing an improved
understanding of this process.
In conclusion, our data argue for the involvement of p25-
Cdk5 in the deregulation of cell-cycle-regulatory proteins that
occurs during neuronal death and identify Rb as having a
function in the survival of neuron as an early target of this
kinase complex.
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